Wasp & Bee Sting Allergy

Prevalence

• Up to 94% of people are stung at least once in their lifetime
• Venom sensitisation: 9.3–38.7% of adults
• Systemic reactions: 0.3–7.5% of adults
• Beekeepers: systemic reactions in 14–43%

Why Specialist Assessment Matters

Venom allergy is the one condition where the risk of future life-threatening anaphylaxis can be dramatically reduced or eliminated through venom immunotherapy (VIT) — the only disease-modifying treatment available. Specialist assessment determines who needs VIT, which venom, and which protocol.

VIT Effectiveness

• Wasp venom: up to 95% protection from future systemic reactions
• Bee venom: approximately 80% protection
• Protection is durable and often persists after completion of a full course

Common Wasp (Vespula vulgaris)

• Most common cause of venom allergy in the UK — particularly in late summer (Aug–Oct)
• Yellow and black, slender body — smooth abdomen, no body hair
• Can sting multiple times; sting does not remain in the skin
• Venom contains phospholipases, hyaluronidases, and antigen 5 (Ves v 5) — the major species-specific allergen
• Highly aggressive when disturbed near nests, particularly in autumn

Honeybee (Apis mellifera)

• Fuzzy, rounded body — distinctly hairy compared to wasps
• Stings once only: barbed sting remains embedded in the skin and the bee dies
• Remove the sting promptly by scraping sideways — do not squeeze the venom sac
• Venom contains melittin, phospholipase A2 (Api m 1), and apamin
• Beekeepers are particularly at risk; bee venom allergy carries a higher rate of VIT treatment reactions than wasp

Hornets & Other Species

• European hornet (Vespa crabro): increasingly common in the UK; venom closely related to wasp; cross-reactivity with wasp VIT is usually sufficient
• Asian hornet (Vespa velutina): an invasive species spreading across the UK since 2016; separate venom testing may be required
• Bumblebees: occasional cause of occupational venom allergy (e.g. glasshouse workers)

Normal Local Reaction

Pain, redness, and swelling at the sting site only. Affects everyone who is stung — this is a direct toxic effect of venom, not allergy. Resolves within 24–48 hours. No specific allergy assessment needed.

Large Local Reaction (LLR)

Swelling extending more than 10 cm from the sting site, crossing a joint, peaking at 24–48 hours and persisting for up to 7–10 days. Uncomfortable but not an indication for VIT. Allergy testing is appropriate to assess underlying sensitisation. Antihistamines and occasionally a short course of oral corticosteroids are used for treatment.

Systemic Allergic Reaction

Symptoms beyond the sting site, affecting one or more body systems. Classified by Mueller grade (below). Specialist assessment and VIT consideration are required for all systemic reactions.

High Priority

• Elevated baseline serum tryptase (>11.4 μg/L) — marker of increased mast cell burden; associated with more severe reactions and reduced VIT protection
• Mastocytosis — systemic or cutaneous; significantly amplifies reaction severity and may require lifelong VIT
• Cardiovascular or respiratory co-morbidities (more common with increasing age)

Sting-Related Factors

• Bee venom allergy — historically associated with more severe reactions than wasp venom
• Sting in a vascular area (head, neck)
• Previous symptomatic sting within 2 months (heightened sensitivity)
• High occupational or recreational exposure (beekeepers, farmers, gardeners, outdoor workers)

Medication Interactions

• Beta-blockers: blunt the response to adrenaline; review with prescribing physician; not an absolute contraindication to VIT but important consideration
• ACE inhibitors: associated with more severe reactions; consider switching to an ARB where clinically feasible before starting VIT
• Tricyclic antidepressants: interact with adrenaline

Lifestyle & Geography

• Living in or regularly visiting rural or remote areas where emergency medical care is not immediately accessible
• Frequent international travel to areas with high Hymenoptera activity
• Living alone without access to prompt assistance in the event of a sting

Two Adrenaline Auto-Injectors

Carry two in-date devices at all times — MHRA requirement. Use immediately if throat tightness, shortness of breath, chest pain, or faintness develops. Call 999. A second dose may be given at 5 minutes if no improvement. From October 2025, EURneffy® (adrenaline nasal spray 2 mg) is available on private prescription as a needle-free alternative or addition for those weighing 30 kg or more. Ask your consultant about suitability.

Non-Sedating Antihistamine

Cetirizine 10 mg, loratadine 10 mg, or fexofenadine 120 mg — for mild reactions without airway, breathing, or circulatory features. Never as a substitute for adrenaline when anaphylaxis features are present. Take immediately after any sting even before symptoms develop.

Written Emergency Action Plan

A personalised plan provided by your allergy consultant, detailing exact steps to take after a sting. Copies should be kept at home, at work, with family carers, and at school (for children). Share with your GP. View our full emergency action plan here →

Medical ID

Wear a MedicAlert bracelet or carry a medical information card identifying venom allergy, prescribed adrenaline, and emergency contact. Essential if alone or incapacitated during a reaction. Register with MedicAlert UK.

Strongly Recommended

• Adults with Mueller Grade III–IV reactions and confirmed venom-specific IgE (by SPT, IDT, or RAST)
• Adults with Grade II reactions and elevated baseline tryptase or mastocytosis
• Children with Grade III–IV reactions

Also Considered

• Adults with Grade I–II reactions and significantly impaired quality of life
• Patients over 60 — 2024 evidence confirms safety and efficacy of ultra-rush VIT in older adults (Bozek et al.)
• Beekeepers or those with unavoidable occupational/recreational exposure

Not Indicated

• Large local reactions alone (no systemic features)
• Normal local reactions
• Venom sensitisation without any clinical reaction history (unless other risk factors present)

95%

Protection for wasp venom allergy after completing VIT

80%

Protection for bee venom allergy after completing VIT

3–5 yrs

Standard VIT course duration. Lifelong VIT considered in mastocytosis.

Durable

Protection often persists for many years after completing a full course of VIT

Conventional Protocol

12–16 weeks build-up | Weekly injections

Weekly injections starting at a very low dose (0.001–0.01 mcg) with incremental dose increases over 12–16 weeks to reach the 100 mcg maintenance dose. Favoured for patients with no urgent exposure risk. Well-established safety profile.

Rush Protocol

4–7 days build-up | Multiple injections per session

Multiple injections per visit over several consecutive days, reaching maintenance in 4–7 days. Appropriate for patients with moderate exposure risk who need faster protection. Administered under close monitoring.

Ultra-Rush Protocol

1–2 days build-up | Available at our clinic

Reaches the 100 mcg maintenance dose over one to two days in a supervised clinic setting. Particularly appropriate for beekeepers, patients with high-frequency occupational exposure, or those travelling to areas with high insect activity. Equally effective to conventional protocols. A 2024 study confirms safety and efficacy of ultra-rush VIT in patients over 60 years, with 86% showing significant reduction in basophil reactivity — comparable to younger patients. Available at the London Allergy and Immunology Centre.

Who Benefits Most

• Patients with systemic mastocytosis requiring VIT
• Those with very high tryptase (>20–25 μg/L)
• Patients who experienced anaphylaxis during a previous VIT attempt
• Ultra-rush VIT candidates with high baseline risk

Evidence Base

Multiple published case series and cohort studies demonstrate that omalizumab pre-treatment (typically 3–4 doses before VIT begins) substantially reduces the rate and severity of systemic reactions during VIT up-dosing, including in patients with systemic mastocytosis. Some patients require prolonged or ongoing omalizumab alongside maintenance VIT.

At Our Clinic

Omalizumab is available privately at the London Allergy and Immunology Centre. Suitability is assessed on an individual basis by your consultant following a full diagnostic workup including baseline tryptase, bone marrow evaluation where indicated, and VIT risk stratification.

Natural History

Children who have experienced Grade I–II systemic reactions (urticaria, mild systemic features) have a generally favourable natural history — many will outgrow their allergy by the third decade of life. The risk of future Grade III–IV reactions following Grade I–II reactions in children is low (approximately 5%). VIT is therefore not routinely recommended for Grade I–II reactions in children without additional risk factors.

When VIT Is Indicated in Children

Grade III–IV reactions — respiratory or cardiovascular involvement — are a strong indication for VIT in children. Also consider for children with Grade I–II reactions if there is confirmed sensitisation plus high exposure risk (e.g. beekeeper’s family) or significantly impaired quality of life.

Large Local Reactions in Children

For children under 10 with large local reactions only, investigations and treatment are generally not necessary unless parents are particularly anxious. If investigated and sensitisation is confirmed, antihistamines and an adrenaline auto-injector may be offered. VIT is not indicated. Our paediatric allergy consultants can advise on an individual basis.

Outdoors

• Wear shoes and socks; avoid walking barefoot on grass
• Wear long sleeves and trousers when gardening
• Avoid brightly coloured, floral-patterned clothing
• Remove nests from your property via a pest control service

Food & Drink

• Keep a lid on sweet drinks outdoors; check cans before drinking
• Keep food covered at picnics and barbecues
• Clear fallen fruit promptly from gardens
• Avoid eating sweet food outdoors in late summer

Fragrances

• Avoid heavily perfumed cosmetics, hair products, or sunscreens outdoors
• Unscented products are preferable in summer
• Some insects are attracted to sweet-smelling products

If an Insect Approaches

• Stay calm and move slowly away
• Do not swat, wave arms, or run suddenly
• Avoid areas known to have active nests
• Keep car windows closed in late summer

I was stung and had hives but no breathing difficulty. Do I need VIT?

Generalised urticaria after a sting is a Grade I systemic reaction. For adults, VIT is considered depending on individual risk factors — including baseline tryptase, comorbidities, exposure frequency, and quality of life. For most children with Grade I reactions, VIT is not routinely recommended due to the favourable natural history. A specialist assessment will clarify whether VIT is appropriate for you specifically.

I tested positive to both bee and wasp IgE. Do I need both venoms treated?

Not necessarily. Dual positivity to both bee and wasp venoms on standard IgE or skin tests is common and often reflects cross-reactivity to shared carbohydrate structures (CCDs) rather than genuine sensitisation to both insects. Component-resolved diagnostics — specifically testing for bee-specific Api m 1 and Api m 10 alongside wasp-specific Ves v 5 — can reliably distinguish genuine double sensitisation from CCD cross-reactivity. This distinction is clinically important: unnecessary dual VIT increases cost, treatment burden, and the risk of adverse reactions.

Can I take beta-blockers while undergoing VIT?

Beta-blockers are not an absolute contraindication to VIT, but they are a relative contraindication — they blunt the response to adrenaline in the event of a systemic reaction during VIT, making anaphylaxis harder to treat. Current EAACI guidance acknowledges this as a risk factor rather than an absolute bar. If possible, switching to an alternative medication (e.g. from a beta-blocker to a calcium channel blocker for hypertension) before starting VIT is advisable. Your consultant will review this with you and liaise with your GP or cardiologist where needed.

My tryptase is elevated. What does this mean for my VIT?

An elevated baseline tryptase suggests increased mast cell burden — which may reflect mastocytosis or clonal mast cell disease, even in the absence of classic skin symptoms. This increases the risk of both severe sting reactions and adverse reactions during VIT up-dosing. It is strongly associated with the need for longer or even lifelong VIT (as protection may wane faster after stopping), and with the potential need for omalizumab co-therapy during VIT. Your consultant will arrange further investigation including serum tryptase repeat testing and, if significantly elevated, a haematology referral for bone marrow assessment.

I have completed 3 years of VIT. Am I now permanently protected?

In the majority of patients, protection persists for many years after completing a standard 3–5 year course of VIT. However, a minority — particularly those with bee venom allergy (failure rate approximately 16–18% vs 4–7% for wasp) or those who experience a systemic reaction during a sting challenge test at the end of treatment — may require extended treatment. All patients who have completed VIT must continue to carry two adrenaline auto-injectors indefinitely and be reviewed annually by their allergy consultant. If you are stung after completing VIT and have a systemic reaction, seek urgent re-assessment.